Caldolor

In the US, Caldolor (ibuprofen systemic) is a member of the drug class nonsteroidal anti-inflammatory agents and is used to treat Fever and Pain.

US matches:

• Caldolor


• Caldolor Injection

Ingredient matches for Caldolor

Ibuprofen

Ibuprofen is reported as an ingredient of Caldolor in the following countries:

• United States

International Drug Name Search

Norethisteron Jenapharm

Norethisteron Jenapharm may be available in the countries listed below.

Ingredient matches for Norethisteron Jenapharm

Norethisterone

Norethisterone 17ß-acetate (a derivative of Norethisterone) is reported as an ingredient of Norethisteron Jenapharm in the following countries:

• Germany

International Drug Name Search

Neupopeg

Neupopeg may be available in the countries listed below.

Ingredient matches for Neupopeg

Pegfilgrastim

Pegfilgrastim is reported as an ingredient of Neupopeg in the following countries:

• Italy


• Slovakia

International Drug Name Search

Simvastatina Ur

Simvastatina Ur may be available in the countries listed below.

Ingredient matches for Simvastatina Ur

Simvastatin

Simvastatin is reported as an ingredient of Simvastatina Ur in the following countries:

• Spain

International Drug Name Search

Monocord

Monocord may be available in the countries listed below.

Ingredient matches for Monocord

Isosorbide Mononitrate

Isosorbide Mononitrate is reported as an ingredient of Monocord in the following countries:

• Israel

International Drug Name Search

Cefactam

Cefactam may be available in the countries listed below.

Ingredient matches for Cefactam

Cefoperazone

Cefoperazone is reported as an ingredient of Cefactam in the following countries:

• Vietnam

Sulbactam

Sulbactam sodium salt (a derivative of Sulbactam) is reported as an ingredient of Cefactam in the following countries:

• Vietnam

International Drug Name Search

Vytorin

Vytorin is a brand name of ezetimibe/simvastatin, approved by the FDA in the following formulation(s):

VYTORIN (ezetimibe; simvastatin - tablet; oral)

• 
  Manufacturer: MSD INTL
  
  Approval date: July 23, 2004
  
  Strength(s): 10MG;10MG, 10MG;20MG, 10MG;40MG, 10MG;80MG ^[RLD]

Has a generic version of Vytorin been approved?

No. There is currently no therapeutically equivalent version of Vytorin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vytorin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
  Patent 5,846,966
  Issued: December 8, 1998
  Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4 -substituted aryl; Ar.sup.3 is aryl or R.sup.5 -substituted aryl; X, Y and Z are --CH.sub.2 --, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6 R.sup.7 ; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sup.5, --CF.sub.3, --CN, --NO.sub.2 and halogen; R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5 OR.sup.6, --O(CO)NR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.6 (CO)R.sup.7, --NR.sup.6 (CO)OR.sup.9, --NR.sup.6 (CO)NR.sup.7 R.sup.8, --NR.sup.6 SO.sub.2 R.sup.9, --COOR.sup.6, --CONR.sup.6 R.sup.7, --COR.sup.6, --SO.sub.2 NR.sup.6 R.sup.7, S(O).sub.0-2 R.sup.9, --O(CH.sub.2).sub.1-10 --COOR.sup.6, --O(CH.sub.2).sub.1-10 CONR.sup.6 R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6 ; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl, aryl or aryl-substituted lower alkyl; R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them, and a process for preparing them.
  
  Patent expiration dates:
  
  
  • September 21, 2013
    
    ✓ 
    Patent use: TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
    ✓ 
    Drug product
  
  
  
  • September 21, 2013
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
    ✓ 
    Drug product
  
  
  
  • March 21, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
  Patent RE37721
  Issued: May 28, 2002
  Inventor(s): Stuart B.; Rosenblum & Sundeep; Dugar & Duane A.; Burnett & John W.; Clader & Brian A.; McKittrick
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • April 25, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
  Patent RE42461
  Issued: June 14, 2011
  Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • April 25, 2017
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 5, 2011 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
  
  
  • December 5, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • January 24, 2015 - CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
  
  

See also...

• Vytorin Consumer Information (Drugs.com)
• Vytorin Consumer Information (Wolters Kluwer)
• Vytorin Consumer Information (Cerner Multum)
• Vytorin Advanced Consumer Information (Micromedex)
• Ezetimibe/Simvastatin Consumer Information (Wolters Kluwer)
• Ezetimibe and simvastatin Consumer Information (Cerner Multum)
• Ezetimibe and simvastatin Advanced Consumer Information (Micromedex)

BetaCreme Lichtenstein

BetaCreme Lichtenstein may be available in the countries listed below.

Ingredient matches for BetaCreme Lichtenstein

Betamethasone

Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of BetaCreme Lichtenstein in the following countries:

• Germany

International Drug Name Search

Callicida Gras

Callicida Gras may be available in the countries listed below.

Ingredient matches for Callicida Gras

Salicylic Acid

Salicylic Acid is reported as an ingredient of Callicida Gras in the following countries:

• Spain

International Drug Name Search

Diphtheria and Tetanus Toxoids (DT) Vaccine

Pronunciation: dif-THEER-ee-ah TET-ah-nus TOX-oids
Generic Name: Diphtheria and Tetanus Toxoids (DT) Vaccine
Brand Name: Generic only. No brands available.

Diphtheria and Tetanus Toxoids (DT) Vaccine is used for:

Immunizing children 7 years of age and younger against diphtheria and tetanus.

Diphtheria and Tetanus Toxoids (DT) Vaccine is a vaccine. It works by providing long-term protection against diphtheria and tetanus by stimulating the body to produce antibodies that neutralize the bacterial toxins that cause these conditions.

Do NOT use Diphtheria and Tetanus Toxoids (DT) Vaccine if:

• you are allergic to any ingredient in Diphtheria and Tetanus Toxoids (DT) Vaccine, including thimerosal


• you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) or neurologic reaction to any previous dose of this or a similar vaccine

Contact your doctor or health care provider right away if any of these apply to you.

Before using Diphtheria and Tetanus Toxoids (DT) Vaccine:

Some medical conditions may interact with Diphtheria and Tetanus Toxoids (DT) Vaccine. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances, especially latex


• if you have an active diphtheria or tetanus infection, fever, or other illness or infection, or you are receiving radiation therapy

Some MEDICINES MAY INTERACT with Diphtheria and Tetanus Toxoids (DT) Vaccine. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Anticoagulants (eg, heparin, warfarin) because the risk of bleeding may be increased by Diphtheria and Tetanus Toxoids (DT) Vaccine


• Immunosuppressive therapy including corticosteroids (eg, prednisone), antimetabolites (eg, methotrexate), alkylating agents (eg, cyclophosphamide), or cytotoxic drugs (eg, dactinomycin) because they may decrease the effectiveness of Diphtheria and Tetanus Toxoids (DT) Vaccine

This may not be a complete list of all interactions that may occur. Ask your health care provider if Diphtheria and Tetanus Toxoids (DT) Vaccine may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Diphtheria and Tetanus Toxoids (DT) Vaccine:

Use Diphtheria and Tetanus Toxoids (DT) Vaccine as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Diphtheria and Tetanus Toxoids (DT) Vaccine is usually administered as an injection at the doctor's office, hospital, or a clinic. The injection is only given intramuscularly (IM, into a muscle), usually in the upper arm or upper thigh. This vaccine is administered as indicated in the recommended immunization schedule for infants and children. The vaccine schedule is started in infants between 6 weeks and 2 months of age and should be completed before the child's seventh birthday. Booster injections may be required at the time of an injury in older children and adults if it has been 5 to 10 years since the last tetanus vaccine was received. Ask the doctor or pharmacist any questions that you may have about Diphtheria and Tetanus Toxoids (DT) Vaccine.


• It is very important to receive each vaccine as scheduled. Be sure to make a note of when each vaccine was given for the child's medical record.


• If you miss a dose of the vaccine series, contact your doctor immediately.

Ask your health care provider any questions you may have about how to use Diphtheria and Tetanus Toxoids (DT) Vaccine.

Important safety information:

• Keep all doctor and lab appointments while using Diphtheria and Tetanus Toxoids (DT) Vaccine.


• If your child has a fever or infection, the doctor may delay giving the vaccine. Discuss the risks and benefits of vaccination with the doctor.


• There are various combinations of vaccines available. Based on previous reactions to vaccines, the doctor will determine the most appropriate ones to use.


• This vaccine is not recommended for persons older than 7 years of age or in INFANTS younger than 6 weeks of age. Safety and effectiveness in these age groups have not been confirmed.


• PREGNANCY and BREAST-FEEDING: Diphtheria and Tetanus Toxoids (DT) Vaccine is not recommended for use in persons older than 7 years of age.

Possible side effects of Diphtheria and Tetanus Toxoids (DT) Vaccine:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Bruising, irritation, itching, redness, swelling, warmth, or a hard lump at the injection site.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty swallowing; high fever; rapid heartbeat; tingling of the hands and feet.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Diphtheria and Tetanus Toxoids (DT) Vaccine:

Store Diphtheria and Tetanus Toxoids (DT) Vaccine in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Keep Diphtheria and Tetanus Toxoids (DT) Vaccine out of the reach of children and away from pets.

General information:

• If you have any questions about Diphtheria and Tetanus Toxoids (DT) Vaccine, please talk with your doctor, pharmacist, or other health care provider.


• Diphtheria and Tetanus Toxoids (DT) Vaccine is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Diphtheria and Tetanus Toxoids (DT) Vaccine. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Diphtheria and Tetanus Toxoids (DT) Vaccine resources

• Diphtheria and Tetanus Toxoids (DT) Vaccine Use in Pregnancy & Breastfeeding
• Diphtheria and Tetanus Toxoids (DT) Vaccine Drug Interactions
• Diphtheria and Tetanus Toxoids (DT) Vaccine Support Group
• 0 Reviews for Diphtheria and Tetanus Toxoids (DT) - Add your own review/rating

Compare Diphtheria and Tetanus Toxoids (DT) Vaccine with other medications

• Diphtheria Prophylaxis
• Tetanus Prophylaxis

Ceftron

Ceftron may be available in the countries listed below.

Ingredient matches for Ceftron

Ceftriaxone

Ceftriaxone is reported as an ingredient of Ceftron in the following countries:

• Bangladesh

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Ceftron in the following countries:

• Sri Lanka

International Drug Name Search

Carperitide (Genetical Recombination)

Carperitide (Genetical Recombination) may be available in the countries listed below.

Ingredient matches for Carperitide (Genetical Recombination)

Carperitide

Carperitide (Genetical Recombination) (JAN) is also known as Carperitide (Rec.INN)

International Drug Name Search

Glossary

JAN	Japanese Accepted Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.